<i>SMPD1</i> mutations, activity, and α‐synuclein accumulation in Parkinson's diseaseRoy N. Alcalay, Ziv Gan‐Or, Victoria Mallett et al.|Movement Disorders|2019Cited by 117
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's diseaseJ. Thomas Hutton, Jerry L. Morris, Bradley C. Hiner et al.|Neurology|1996Cited by 89
Transdermal dopaminergic D<sub>2</sub> receptor agonist therapy in Parkinson's disease with N‐0923 TDS: A double‐blind, placebo‐controlled studyJ. Thomas Hutton, Jerry L. Morris, Leo Verhagen Metman et al.|Movement Disorders|2001Cited by 60